L26/O-210 Endometrial microbiome and endometritis testing: who is it for?
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von E. Theodorou und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Do endometrial microbiome and endometritis profiles differ among subfertile patients, those with recurrent implantation failure (RIF), and those with recurrent pregnancy loss (RPL)? Summary answer Previous implantation failures and previous miscarriages were not linked to a higher likelihood of abnormal endometrial microbiome or endometritis results following endometrial sampling. What is known already Microbiome testing in fertility care has gained significant interest as a potentially modifiable factor influencing embryo implantation. The ESHRE guidance suggests that the investigation and treatment of endometritis can be considered in RIF cases and the reported incidence of chronic endometritis in the RIF population ranges between 14% and 67.5%. Accumulating evidence suggests that the uterine microbiome of women experiencing pregnancy loss or RPL have higher species diversity and reduced lactobacillus abundance compared to healthy controls. The absence of a standardised, optimal method for microbiome assessment contributes to inconsistent evidence regarding the clinical value of microbiome testing. Study design, size, duration Retrospective single-centre study. Results were analysed from all subfertile patients who had endometrial sampling for uterine microbiome and endometritis testing from 2021 to 2024. Endometrial sampling was performed using a Pipelle endometrial suction catheter (Pipelle®; CooperSurgical) following the same protocol and aseptic technique in the luteal phase of the cycle. Endometrial microbiome and chronic endometritis were assessed using next-generation sequencing–based testing (EMMA/ALICE; Igenomix). Participants/materials, setting, methods RIF was defined as ≥ three implantation failures of untested embryos under 40 years old or ≥ two implantation failures of euploid embryos at any age. RPL was defined as ≥ two pregnancy losses. Microbiome results were classified as normal or abnormal. For a sub-analysis, we grouped abnormal results into 3 categories: Intermediate (non-lactobacillus dominant, mild dysbiosis), ‘ultralow biomass ULB’ and abnormal. The endometritis testing was reported as negative or positive. Main results and the role of chance 769 EMMA and ALICE results were included in the analysis. The number of previous pregnancies/live births/miscarriages/implantation failures did not affect the chance of a positive result for chronic endometritis. Women who had no previous pregnancies/miscarriages and no previous implantation failures had comparable risk of testing positive for chronic endometritis with women who had RIF/RPL (13.1% vs 11% vs 13.5%). The body mass index did not influence results. The chances of having an abnormal result appeared to be increasing with age. Similarly, the results for the endometrial microbiome were not significantly different amongst the patient populations. The percentage of women with abnormal microbiome was 28.4% for the RPL group, 21.6% for the RIF group, 28% for women with no previous miscarriages and 27.1% for women with no previous implantation failures. Following sub-analysis, women with > = 2 live births had more frequently abnormal results compared to women with no previous live births (37.5% vs 24.2%). Regression analysis suggested that women with RIF had a higher frequency of ULB. The risk for an abnormal EMMA/ALICE result was higher with age but did not increase with the number of previous implantation failures or the number of previous pregnancy losses. Limitations, reasons for caution Single-centre, retrospective study. The samples were taken under aseptic technique, but due to the nature of the procedure, contamination from vaginal/cervical microbiota cannot be excluded. Clinical outcomes following treatment based on test results were not evaluated, highlighting the need for further studies to determine the clinical value of testing. Wider implications of the findings This retrospective study did not identify a patient subgroup more likely to benefit from endometrial microbiome or chronic endometritis assessment. Women with history of RIF / RPL showed results comparable to the general subfertile population, providing important information to guide patient counselling. Trial registration number No
Zitieren
APA
Theodorou, E., Chronopoulou, E., Falvey, K., & Ozturk, O. (2026). L26/O-210 Endometrial microbiome and endometritis testing: who is it for?. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.208
Vancouver
Theodorou E, Chronopoulou E, Falvey K, Ozturk O. L26/O-210 Endometrial microbiome and endometritis testing: who is it for?. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.208
BibTeX
@article{Theodorou2026,
author = {Theodorou, E. and Chronopoulou, E. and Falvey, K. and Ozturk, O.},
title = {L26/O-210 Endometrial microbiome and endometritis testing: who is it for?},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.208}
}
EUVIMED